Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (18)

« Back to Publications

Double hit ultra-high risk myeloma treated with isatuximab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide (Isa-VRDc) induction and isa-VRD consolidation: Initial results of the UK myeloma research alliance (UKMRA) RADAR trial in newly diagnosed transplant eligible patients

Ramasamy K. et al, (2025), Blood, 146, 98 - 98

Long-read RNA sequencing of first multiple myeloma patient cohort reveals landscape of variant expression in newly diagnosed patients from the UKMRA RADAR trial

Hudson-Lund B. et al, (2025), Blood, 146, 2141 - 2141

NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myeloma.

Agarwal G. et al, (2025), Br J Haematol, 207, 2167 - 2172

nti-Adhesion Properties of KTX-1001, a Selective NSD2/MMSET Inhibitor, Enhance Carfilzomib Sensitivity in Multiple Myeloma

Nandana D. et al, (2025), Clinical Lymphoma Myeloma and Leukemia, 25, S213 - S214

Quantitative liver function imaging and whole genome sequencing - Effective modalities for a new era in personalised decision-making for operable colorectal liver metastases?

Welsh F. et al, (2025), HPB (Oxford), 27, 553 - 561

High Expression of NSD2 in Non t (4;14) Newly-Diagnosed Multiple Myeloma Patients May Mimic t (4;14) Biology

Samur M. et al, (2025), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 25

nti-Adhesion Properties of KTX-1001, a Selective NSD2/MMSET Inhibitor, Enhance Carfilzomib Sensitivity in Multiple Myeloma

Nandana D. et al, (2025), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 25

P-219 Longitudinal Analysis of t(11; 14) and t(4; 14) Genomes Reveals Distinct Evolutionary Trajectories in Multiple Myeloma

Hudson-Lund B. et al, (2024), Clinical Lymphoma Myeloma and Leukemia, 24, S163 - S164

Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial

Gooding S. et al, (2024), BLOOD, 144, 3333 - 3334

Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data

Ansari-Pour N. et al, (2024), BLOOD, 144, 1909 - 1910

Longitudinal Analysis of t(11;14) and t(4;14) Genomes Reveals Distinct Evolutionary Trajectories in Multiple Myeloma

Hudson-Lund B. et al, (2024), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 24, S163 - S164

Acquisition of 1pLOH-1qGain Is a Frequent Trajectory in Expanding Relapsed/Refractory Myeloma Subclones

Ansari-Pour N. et al, (2023), Blood, 142, 1999 - 1999

Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients

Agarwal G. et al, (2023), Blood, 142, 644 - 644

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma.

Gooding S. et al, (2022), Blood, 140, 1816 - 1821

Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma.

Sudha P. et al, (2022), Clin Cancer Res, 28, 2854 - 2864

Load More